OR WAIT null SECS
October 03, 2024
How the Republican and Democrat presidential candidates might appeal to voters on this topic is starting to be seen.
September 28, 2024
Innovative solutions are making personalized cell and gene therapies accessible to all.
September 24, 2024
Emerging therapies, such as cell and gene therapies, come with unique challenges that must be planned for in advance.
September 18, 2024
Lilly has increased its manufacturing investment for biologics in Limerick, Ireland, by $1 billion while launching its new $800 million facility in Kinsale.
September 11, 2024
The finalists for the 2024 CPHI Pharma Awards are spread across 14 categories, which include future leaders, women of the year, and an “at the heart of pharma” category.
August 27, 2024
With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.
August 21, 2024
Under a deal worth potentially up to $1.3 billion, Merck, known as MSD outside of the United States and Canada, will acquire CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical.
August 19, 2024
Genentech will leverage Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines to address certain neurodegenerative diseases.
August 09, 2024
Under the license agreement, Andelyin Biosciences will expand its AAV Curator Platform by including MyoAAV plasmids developed by Broad Institute of MIT and Harvard.
August 08, 2024
With a $15 million fund-raising goal, US Specialty Formulations plans to invest in expanding its biopharma facility in Allentown, Pa.